The final section of the Endocrine Society of Australia (ESA) Position Statement on Male Hypogonadism (Part 2: treatment and therapeutic considerations) was published in the September issue of the Medical Journal of Australia, complementing Part 1: assessment and indications for … Continue reading
Observational data suggest that testosterone levels in men may be a reversible risk factor for T2D and therefore inclusion of testosterone may enhance the performance of current type 2 diabetes risk tools. There are currently at least seven risk models … Continue reading
The Endocrine Society of Australia (ESA) Position Statement on Male Hypogonadism (part 1): Assessment and Indications for Testosterone Therapy has just been published in the Medical Journal of Australia, updating the ESA guidelines from 2000. Developed by leading Australian endocrinologists, … Continue reading
Although favourable body composition changes are one of the most consistent findings in trials to date, the role of testosterone therapy in men with diabetes remains to be defined.
Andrology Australia and the Endocrine Society of Australia have released a joint statement providing some suggestions that may assist with understanding the changes and implementing the new PBS criteria for prescription of testosterone.
A recent study found that low testosterone is associated with more advanced atherosclerotic disease markers in middle-aged men with type 2 diabetes. However, it is not clear that testosterone replacement in older men with diabetes will reduce the risk of cardiovascular events.
Findings from mortality follow-up from the Health In Men Study suggest that for an older man being treated with testosterone, the target should be in the middle of the normal range, rather than the high end.
A recent study found that there is insufficient evidence to support the supposed link between testosterone and mood and behaviour effects such as aggression and risk taking.